9th Jan 2006 07:00
Dechra Pharmaceuticals PLC09 January 2006 Issued by Citigate Dewe Rogerson Limited, BirminghamDate: Monday, 9 January 2006 Embargoed: 7.00am Dechra Pharmaceuticals PLC Product Development and Trading Update Dechra Pharmaceuticals PLC ("the Group") issues the following update toshareholders, ahead of publication of the Group's Interim results for the sixmonths ended 31 December 2005, which are scheduled to be announced on Tuesday 28February 2006. Product Development Update Our strategic focus continues to be the ongoing development of our ownveterinary pharmaceutical products. It is pleasing to report that through the mutual recognition procedure, we havegained approval for Vetoryl Capsules in all 19 EU countries applied for.Marketing will commence via our European partners in the key territories priorto the end of this financial year. The Group also continues to make progress on Vetoryl Capsules in the USA.Feedback has been received from the FDA on both safety and efficacy, and as aresult we will shortly commence supportive USA based trials to complete theregulatory application package. The trial work is expected to be completed inlate 2007. Current Trading Current trading has continued in line with management expectations, with Grouprevenue growth of approximately 11%. This reflects both strong market conditionsand increased market share. As budgeted, product development expenditure will be significantly higher duringthe first half of the current financial year at approximately £0.8 million(2004: £0.3 million). We remain confident that Group performance for the financial year ending 30 June2006 will be in line with management expectations. Enquiries:Ian Page, Chief Executive Fiona Tooley, DirectorSimon Evans, Group Finance Director Katie Dale, Senior Account ManagerDechra Pharmaceuticals PLC Citigate Dewe RogersonTel: 01782 771100 Tel: 0121 455 8370Mobile: 07775 642222 (IP) or 07775 642220 (SE) Mobile: 07785 703523 (FMT)www.dechra.com This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
DPH.L